Activiomics Ltd. has developed a groundbreaking and patented technology that will enable a transformation in the way in which biomarkers are identified, diagnostics are developed and drug candidates are identified and profiled.
Activiomics' technology centres around novel mass spectrometry based approaches for the global quantitative analysis of phosphorylation sites. Phosphorylation is critical mediator all cellular processes and hence sites of phosphorylation represent an important class of novel biomarkers. Activiomics' TIQUAS (Targeted In-depth QUAntification of cell Signalling) technology enables the quantification of thousands of phosphorylation events from a given tissue sample and the subsequent markers of response that are identified will enable the development of future diagnostics.
Funding Rounds (1) - $805kUpdate
Current Team (4)Update
|Mar 4, 2014||ipgroupplc.com - Retroscreen Virology Group plc - Acquisition of Activiomics Ltd IP Group plc|
|Mar 16, 2011||equityhelpdesk.com - Activiomics raises 805000 in unknown round|
London, EC3V 3ND